Medscape is available in 5 Language Editions – Choose your Edition here.


Trench Fever

  • Author: Sarah Perloff, DO, FACP; Chief Editor: Mark R Wallace, MD, FACP, FIDSA  more...
Updated: Jan 28, 2015

Practice Essentials

Trench fever is a clinical syndrome caused by infection with Bartonella quintana; the condition was first described during World War I. Contemporary B quintana disease, commonly referred to as urban trench fever, is typically found in homeless, alcoholic, and poor populations.

The human body louse Pediculus humanus var corporis is the major vector involved in trench fever transmission[1, 2] (see the image below).

Dorsal view of female body louse, Pediculus humanuDorsal view of female body louse, Pediculus humanus var corporis. This louse is a known vector responsible for transmission of epidemic typhus, trench fever, and Asiatic relapsing fever; it also causes dermatitic condition known as pediculosis. Image courtesy of Centers for Disease Control and Prevention.

Signs and symptoms

Classic symptoms of trench fever include the following:

  • Clinical incubation period of 3-48 days
  • Acute-onset fever in any of 3 distinct patterns, all of which are often associated with chills and diaphoresis: Abortive, relapsing (the most common pattern), or continuous
  • Acute-onset frontal or retro-orbital headache, often associated with a stiff neck and photophobia
  • Neuropsychiatric symptoms, such as weakness, depression, restlessness, and insomnia
  • Conjunctivitis
  • Dyspnea
  • Diffuse abdominal pain, often associated with anorexia, nausea, vomiting, weight loss, diarrhea, and constipation
  • Bone pain, particularly involving the shins; loin pain
  • Erythematous, macular rash

Urban trench fever typically includes 1 or more of these symptoms, but the presentation tends to be more variable.

Three additional syndromes are associated with B quintana infection, as follows:

  • Chronic lymphadenopathy – Enlarged cervical lymph nodes, without fever or other associated symptoms
  • Bacillary angiomatosis – characteristic skin lesions, with or without regional lymphadenopathy
  • B quintana endocarditis – Fever, new murmur, and heart failure; embolic phenomena

Characteristics of classic trench fever were fairly consistent, as follows:

  • Fever up to 104°F
  • Toxic initial appearance associated with prostration
  • Characteristic blanching, erythematous, macular rash
  • Conjunctivitis at the onset of illness
  • Paroxysmal tachycardia, paralleling the fever and exacerbated with exercise
  • Splenomegaly in more prolonged courses
  • Bone and muscle tenderness
  • Loss of Achilles reflex
  • Associated lice infestation

Physical findings of urban trench fever are more variable, but tend to include the following:

  • Presence of rash, fever, conjunctivitis, bone tenderness, splenomegaly, and neuropsychiatric signs vary, and the characteristic signs are generally less prevalent than in the classic cases
  • Nonspecific findings such as weight loss and weakness

Common findings in associated syndromes of urban trench fever are as follows:

  • Chronic lymphadenopathy – Lymphatic involvement of the cervical and mediastinal lymph nodes; afebrile and otherwise asymptomatic
  • Bacillary angiomatosis (immunocompetent) – Presence of one or more papules that progress to nodules that may be localized or disseminated; associated regional adenopathy; afebrile
  • Bacillary angiomatosis (immunocompromised) – Lesions are generally more widespread and are more likely to involve visceral organs than in the immunocompetent patient
  • B quintana endocarditis – Fever and murmur; typically involves the left-sided heart valves; embolic events; possible heart failure

Many patients with microbiologic or serologic evidence of B quintana infection are asymptomatic.

See Presentation for more details.


B quintana infection is difficult to diagnose in the laboratory. The following studies may be useful:

  • Blood cultures
  • Immunofluorescent assays (IFAs) for immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody levels for both B quintana and Bartonella henselae
  • Enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA)
  • Polymerase chain reaction (PCR)–based genomic assays and histochemical stains for direct detection of Bartonella DNA in both tissue and blood
  • Biopsy of skin, lymph node, cardiac valve, or other tissue

See Workup for more details.


Current antibiotic recommendations for each of the identified clinical syndromes associated with B quintana in immunocompetent patients are as follows:

  • Trench fever/urban trench fever – Doxycycline 100 mg PO twice daily for 28 days plus gentamicin 3 mg/kg/day IV for 14 days; macrolides and ceftriaxone are also effective
  • Chronic B quintana bacteremia – Doxycycline 100 mg PO twice daily for 28 days and gentamicin 3 mg/kg/day IV for 14 days; in some cases, longer therapy (up to 4 years) may be required; serial cultures demonstrating eradication of the bacteremia are pivotal in determining duration of therapy
  • Chronic lymphadenopathy – Erythromycin 500 mg PO 4 times daily for 3 months (first-line therapy) or doxycycline 100 mg PO twice daily for 3 months (alternative); in difficult cases, gentamicin 3 mg/kg/day IV for 14 days can be added
  • Bacillary angiomatosis – Erythromycin 500 mg PO 4 times daily for 3 months (first-line therapy) or doxycycline 100 mg PO twice daily for 3 months (alternative); in refractory cases, gentamicin 3 mg/kg/day IV for 14 days can be added; fluoroquinolones and ceftriaxone may also be considered
  • B quintana endocarditis – Doxycycline 100 mg PO twice daily for 6 weeks plus gentamicin 3 mg/kg/day IV for 14 days; if culture results are negative, ceftriaxone should be added

Surgical biopsy may help diagnose B quintana endocarditis, lymphadenopathy, or bacillary angiomatosis. Valve replacement surgery is required in most cases of B quintana endocarditis.

See Treatment and Medication for more details.



Trench fever is a clinical syndrome caused by infection with Bartonella quintana. The condition was first described during World War I, when it affected nearly 1 million soldiers.[3, 4, 1, 2] It has been known by several different names, including quintan fever, 5-day fever, shin bone fever, tibialgic fever, Wolhynia fever, and His-Werner disease.

DNA studies have demonstrated that many soldiers in Napoleon’s Grand Army at Vilnius in the 19th century were infected with B quintana. In addition, B quintana DNA was found in a 4000-year-old human tooth in Roaix, France.[5, 6] Reports of trench fever outbreaks stopped after World War I and then reappeared transiently on the Eastern Front in Europe during World War II.

By the end of World War I, the human body louse Pediculus humanus was recognized as the likely vector for trench fever transmission.[1, 2] Rickettsia -like organisms in the body and feces of P humanus were postulated to be the cause. In 1969, Vinson et al successfully cultivated the causative organism (then called Rickettsia quintana) from a sick patient and reproduced the disease by inoculating healthy volunteers.[7] The organism was briefly placed in the genus Rochalimaea before being reclassified as Bartonella quintana in 1993.

During World War I, trench fever was characterized by the abrupt onset of fever, malaise, myalgias, headache, transient macular rashes of the torso, pain in the long bones of the leg (shins), and splenomegaly.[8, 9, 1, 2, 3, 4, 10, 11] Typical periodic cycles of fever, chills, and sweats occurred at 5-day intervals, resulting in prolonged disability lasting 3 months or longer in young soldiers. However, no deaths attributable to trench fever have ever been reported.

Over the past 3 decades, Bartonella species have emerged as a cause of bacteremia, angioproliferative disease (eg, bacillary angiomatosis), and endocarditis in patients with and without HIV infection. In 1995, B quintana was found to cause bacteremia in 10 homeless, HIV-negative alcoholics.[12] In 1999, B quintana endocarditis was described in 3 HIV-negative homeless alcoholic men.[13] These cases suggest that B quintana disease is not limited to wartime outbreaks or immunocompromised persons.

Subsequently, sporadic cases and small clusters of B quintana infection have been described worldwide and appear to be associated with poor sanitation, poor hygiene, alcoholism, and malnutrition—all of which are commonly seen in both classic and urban trench fever cases. Seroprevalence studies suggest that B quintana infection is more common than is clinically recognized and that many infections are subclinical.

The term urban trench fever is applied to contemporary B quintana disease. Urban trench fever is typically found in homeless, alcoholic, and poverty-stricken populations, among whom poor personal hygiene is common. The infection affects both immunocompetent and immunocompromised persons. Some (but not all) persons with urban trench fever have evidence of louse infestation.

The spectrum of disease associated with B quintana infection includes asymptomatic infection, urban trench fever, angioproliferative disease, chronic lymphadenopathy, bacteremia, and endocarditis.[9, 14, 15]



The human body louse P humanus var corporis is the major vector involved in trench fever transmission (see the image below).[1, 2]

Dorsal view of female body louse, Pediculus humanuDorsal view of female body louse, Pediculus humanus var corporis. This louse is a known vector responsible for transmission of epidemic typhus, trench fever, and Asiatic relapsing fever; it also causes dermatitic condition known as pediculosis. Image courtesy of Centers for Disease Control and Prevention.

After B quintana is introduced into the human body, it invades erythrocytes and endothelial cells, where it is protected from the host’s humoral immune response.[16] Intraerythrocytic B quintana colonization is largely limited to human beings,[9, 14] while the invasion of vascular endothelial cells is less species-specific.[17] Monocytes from homeless individuals with chronic B quintana bacteremia have been shown to overproduce interleukin (IL)–10, resulting in an attenuated immune response that may facilitate the bacterial persistence.[18] These same patients generate a poorer humoral response than patients with endocarditis, in whom the inflammatory response is more dramatic and bacteremia less frequent.[19]

Once the organism invades and begins to multiply within endothelial cells, proinflammatory cytokines are activated, apoptosis suppressed, and vascular proliferation initiated.[20] These changes result in systemic symptoms, bacteremia, endovascular infection, and lymphatic enlargement. The relationship between the endothelial vascular proliferation and the destructive valvular lesions of B quintana endocarditis is unknown. A potential connection might be the presence of variably expressed outer-membrane proteins in some strains of B quintana. These proteins induce secretion of vascular endothelial growth factor and are associated with increased rates of invasion.[21]

Despite this possible immunologic association, the histologic features of these two clinical variants differ.[9] The pathogenesis of B quintana –associated disease suggests that bacteremia is an early occurrence common to all of the various syndromes attributed to it. In some patients, the bacteremia lasts for a few days, whereas, in others, it lasts for months to years.[14]



B quintana causes both trench fever and urban trench fever.[9, 7] Humans are the predominant reservoir of the pathogen, although infection has been documented in some nonhuman primates and in cats.[22, 23, 24, 25] In infected persons, the organisms can be found in human blood, tissues (particularly skin), and urine.[9]

B quintana bacteremia may be intermittent or prolonged for years, suggesting that blood-sucking arthropods are efficient transmitters of B quintana infection.[16, 14] External parasitic infestations are also associated with conditions of squalor. Although the body louse P humanus is the major vector for both trench fever and urban trench fever, its presence is not always demonstrated in patients with urban trench fever.[7, 13, 26]

Breaks in the skin contaminated by louse feces and arthropod bites are documented portals of entry. Other possible vectors include mites, ticks, and fleas.[9] A 2014 study showed that cat fleas (Ctenocephalides felis) can ingest B quintana and release viable bacteria into their feces.[27] Contamination of mucous membranes, transfusion, transplantation, and IV drug abuse are also potential avenues of entry. Human-to-human transmission of trench fever has not been described.



Predisposing factors for B quintana infection include war, famine, malnutrition, homelessness, alcoholism, intravenous (IV) drug abuse, and poor hygiene.

United States statistics

B quintana was found in the lice of 33.3% of body lice–infested and 25% of head lice–infested homeless persons in California.[28] In one study, 20% of the patients in a downtown Seattle clinic that serves a homeless indigent population had microimmunofluorescent antibody titers of 1:64 or greater to Bartonella species.[29] Multivariate analysis of these patients revealed that alcohol abuse was the only independent variable associated with seropositivity. It is difficult, however, to ascertain the true incidence of urban trench fever, as most infected individuals are asymptomatic. Moreover, the disease occurs sporadically and in small clusters of homeless persons.

International statistics

B quintana –related illness has been found on every continent except Antarctica. Well-performed seroprevalence studies have identified patients with B quintana antibodies in France, Greece, Sweden, Japan, Brazil, Croatia, and Peru.[19, 30, 31, 32, 33, 34, 35] Cases of culture-negative endocarditis with antibody titers positive for B quintana have been reported in Europe, Australia, Japan, Tunisia, and India.[36, 37, 38, 39, 40]

Age-, sex-, and race-related demographics

Whereas trench fever described during wartime typically affected young soldiers, urban trench fever typically affects middle-aged adults. Rare cases of Bartonella endocarditis and central nervous system (CNS) infection have been described in children.

Because trench fever was historically an infection of soldiers, most of the cases documented during World Wars I and II were in males. Cases of urban trench fever described since 1995 have also predominantly involved males, reflecting the disproportionate representation of males in the homeless alcoholic population.

No convincing data suggest that urban trench fever or other syndromes caused by B quintana infection have a racial or ethnic predilection.



In most immunocompetent hosts, B quintana infection is self-limited unless endocarditis occurs. In immunocompromised hosts, however, B quintana infection tends to be more severe and may result in death.

During World War I, trench fever resulted in significant morbidity and prolonged disability but no recognized mortality. Contemporary descriptions of B quintana endocarditis in homeless alcoholic males have found mortality rate to be as high as 12%, with most deaths related to complications of endocarditis or to the surgery used in its treatment.[41, 42]


Patient Education

Patients should be educated about practicing good personal hygiene and improving their living conditions. Vector control of the body louse should also be explained.

Contributor Information and Disclosures

Sarah Perloff, DO, FACP Director, Antibiotic Stewardship Program, Associate Program Director, Internal Medicine Residency, Program Director, Infectious Diseases Fellowship, Einstein Medical Center

Sarah Perloff, DO, FACP is a member of the following medical societies: American College of Physicians, American Osteopathic Association, Infectious Diseases Society of America, HIV Medicine Association

Disclosure: Nothing to disclose.


Percy Guanzon Balderia, MD Resident Physician, Department of Medicine, Albert Einstein Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Mark R Wallace, MD, FACP, FIDSA Clinical Professor of Medicine, Florida State University College of Medicine; Clinical Professor of Medicine, University of Central Florida College of Medicine

Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society, Florida Infectious Diseases Society

Disclosure: Nothing to disclose.


Michael A Forgione Jr, MD Chief of Infectious Diseases, Instructor, Department of Medicine, Keesler Medical Center

Disclosure: Nothing to disclose.

Thomas M Kerkering, MD Chief of Infectious Diseases, Virginia Tech Carilion School of Medicine

Thomas M Kerkering, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Public Health Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Medical Society of Virginia, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Alfred Scott Lea, MD Associate Professor of Medicine, Department of Medicine, Division of Infectious Diseases, University of Texas Medical Branch School of Medicine

Alfred Scott Lea, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Certified Wound Specialists, American College of Physicians, Harris County Medical Society, Infectious Diseases Society of America, and Texas Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Jeffrey M Zaks, MD Clinical Associate Professor of Medicine, Wayne State University School of Medicine; Vice President, Medical Affairs, Chief Medical Officer, Department of Internal Medicine, Providence Hospital

Jeffrey M Zaks, MD is a member of the following medical societies: American College of Cardiology, American College of Healthcare Executives, American College of Physician Executives, and American Medical Association

Disclosure: Nothing to disclose.


The author would like to thank A Clinton White, MD, for his encouragement and suggestions during the composition of this article.

The authors and editors of Medscape Reference also gratefully acknowledge the contributions of previous author Eleftherios Mylonakis, MD, and previous coauthor Michael Forgione, MD, to the development and writing of this article.

  1. McNee JW, Renshaw A, Brunt EH. Trench Fever. Brit Med J. 1916. i:225-34.

  2. Byam W, Carroll JH, Churchill L, Dimond VE, Sorapure VE, Wilson RM, et al. Trench fever: a louse-born disease. London: Oxford University Press; 1919.

  3. Graham JHP. A note on a relapsing febrile illness of unknown origin. Lancet. 1915. ii:703-4.

  4. Hunt GH, Rankin AC. Intermittent fever of obscure origin occurring among British soldiers in France. The so-called "trench fever.". Lancet. 1915. ii:1133-6.

  5. Raoult D, Dutour O, Houhamdi L, Jankauskas R, Fournier PE, Ardagna Y, et al. Evidence for louse-transmitted diseases in soldiers of Napoleon's Grand Army in Vilnius. J Infect Dis. 2006 Jan 1. 193(1):112-20. [Medline].

  6. Drancourt M, Tran-Hung L, Courtin J. Bartonella quintana in a 4000-year-old human tooth. J Infect Dis. 2005 Feb 15. 191(4):607-11. [Medline].

  7. Vinson JW, Varela G, Molina-Pasquel C. Trench fever. 3. Induction of clinical disease in volunteers inoculated with Rickettsia quintana propagated on blood agar. Am J Trop Med Hyg. 1969 Sep. 18(5):713-22. [Medline].

  8. Ruhrah J. Infectious Disease. Hare HA, ed. Progressive Medicine. Philadelphia and New York: Lea & Febiger; 1919. Vol 1: 151-244.

  9. Maurin M, Raoult D. Bartonella (Rochalimaea) quintana infections. Clin Microbiol Rev. 1996 Jul. 9(3):273-92. [Medline].

  10. Biswas S, Rolain JM. Bartonella infection: treatment and drug resistance. Future Microbiol. 2010 Nov. 5(11):1719-31. [Medline].

  11. Peacock A, Pearson W. The Peacock versus the louse (pediculus humanus corporis): one soldier's contribution to combating trench fever in the First World War. J R Coll Physicians Edinb. 2010 Sep. 40(3):256-62. [Medline].

  12. Matera G, Liberto MC, Joosten LA, Vinci M, Quirino A, Pulicari MC, et al. The Janus face of Bartonella quintana recognition by Toll-like receptors (TLRs): a review. Eur Cytokine Netw. 2008 Sep. 19(3):113-8. [Medline].

  13. Brouqui P, Lascola B, Roux V, Raoult D. Chronic Bartonella quintana bacteremia in homeless patients. NEJM. Jan/1999. 340(3):184-9. [Medline].

  14. Foucault C, Brouqui P, Raoult D. Bartonella quintana characteristics and clinical management. Emerg Infect Dis. Feb/2006. 12(2):217-23. [Medline].

  15. Piérard-Franchimont C, Quatresooz P, Piérard GE. Skin diseases associated with Bartonella infection: facts and controversies. Clin Dermatol. 2010 Sep-Oct. 28(5):483-8. [Medline].

  16. Rolain JM, Foucault C, Guieu R, Lascola B, Brouqui P, Raoult D. Bartonella quintana in human erythrocytes. Lancet. July/2002. 360(9328):226-8. [Medline].

  17. Dehio C. Molecular and cellular basis of bartonella pathogenesis. Annu Rev Microbiol. 2004. 58:365-90. [Medline].

  18. Capo C, Amirayan-Chevillard N, Broqui P, Raoult D, Mege JL. Bartonella quintana bacteremia and overproduction of interleukin-10: Model of bacterial persistence in homeless people. JID. Oct, 2003. 187:837-44. [Medline].

  19. LaScola B, Raoult D. Culture of Bartonella quintana and Bartonella henselae from human samples: a 5-year experience (1993 to 1998). J Clin Microbiol. 1999 Jun;37(6):1899-905. [Medline]. [Full Text].

  20. Liberto MC, Matera G, Lamberti AG, Barreca GS, Quirino A, Foca A. In vitro Bartonella quintana infection modulates the programmed cell death and inflammatory reaction of endothelial cells. Diagn Microbiol Infect Dis. Feb/2003. 45(2):107-15. [Medline].

  21. Schulte B, Linke D, Klumpp S, Schaller M, Riess T, Autenrieth IB, et al. Bartonella quintana variably expressed outer membrane proteins mediate vascular endothelial growth factor secretion but not host cell adherence. Infect Immun. 2006 Sep. 74(9):5003-13. [Medline]. [Full Text].

  22. O'Rourke LG, Pitulle C, Hegarty BC, Kraycirik S, Killary KA, Grosenstein P, et al. Bartonella quintana in cynomolgus monkey (Macaca fascicularis). Emerg Infect Dis. 2005 Dec. 11(12):1931-4. [Medline]. [Full Text].

  23. Ohl ME, Spach DH. Bartonella quintana and urban trench fever. Clin Infect Dis. 2000 Jul. 31(1):131-5. [Medline].

  24. Breitschwerdt EB, Maggi RG, Sigmon B, Nicholson WL. Isolation of Bartonella quintana from a woman and a cat following putative bite transmission. J Clin Microbiol. 2007 Jan. 45(1):270-2. [Medline]. [Full Text].

  25. La VD, Tran-Hung L, Aboudharam G, Raoult D, Drancourt M. Bartonella quintana in domestic cat. Emerg Infect Dis. 2005 Aug. 11(8):1287-9. [Medline]. [Full Text].

  26. Brouqui P, Houpikian P, Dupont HT, Toubiana P, Obadia Y, Lafay V, et al. Survey of the seroprevalence of Bartonella quintana in homeless people. Clin Infect Dis. 1996 Oct. 23(4):756-9. [Medline].

  27. Kernif T, Leulmi H, Socolovschi C, Berenger JM, Lepidi H, Bitam I, et al. Acquisition and excretion of Bartonella quintana by the cat flea, Ctenocephalides felis felis. Mol Ecol. 2014 Mar. 23(5):1204-12. [Medline].

  28. Bonilla DL, Kabeya H, Henn J, Kramer VL, Kosoy MY. Bartonella quintana in body lice and head lice from homeless persons, San Francisco, California, USA. Emerg Infect Dis. 2009 Jun. 15(6):912-5. [Medline]. [Full Text].

  29. Jackson LA, Spach DH. Emergence of Bartonella quintana infection among homeless persons. Emerg Infect Dis. 1996 Apr-Jun. 2(2):141-4. [Medline]. [Full Text].

  30. Tea A, Alexiou-Daniel S, Arvanitidou M, Diza E, Antoniadis A. Occurrence of Bartonella henselae and Bartonella quintana in a healthy Greek population. Am J Trop Med Hyg. 2003 May. 68(5):554-6. [Medline].

  31. Ehrenborg C, Byström R, Hjelm E, Friman G, Holmberg M. High Bartonella spp. seroprevalence in a Swedish homeless population but no evidence of trench fever. Scand J Infect Dis. 2008. 40(3):208-15. [Medline].

  32. Seki N, Sasaki T, Sawabe K, Sasaki T, Matsuoka M, Arakawa Y, et al. Epidemiological studies on Bartonella quintana infections among homeless people in Tokyo, Japan. Jpn J Infect Dis. 2006 Feb. 59(1):31-5. [Medline].

  33. da Costa PS, Brigatte ME, Greco DB. Antibodies to Rickettsia rickettsii, Rickettsia typhi, Coxiella burnetii, Bartonella henselae, Bartonella quintana, and Ehrlichia chaffeensis among healthy population in Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2005 Dec. 100(8):853-9. [Medline].

  34. Raoult D, Birtles RJ, Montoya M, Perez E, Tissot-Dupont H, Roux V, et al. Survey of three bacterial louse-associated diseases among rural Andean communities in Peru: prevalence of epidemic typhus, trench fever, and relapsing fever. Clin Infect Dis. 1999 Aug. 29(2):434-6. [Medline].

  35. Vilibic-Cavlek T, Karlovic-Martinkovic D, Ljubin-Sternak S, Tabain I, Persic Z, Mlinaric-Galinovic G. High prevalence of Bartonella henselae and Bartonella quintana antibodies in Croatian patients presenting with lymphadenopathy. Pol J Microbiol. 2012. 61(4):315-7. [Medline].

  36. Drancourt M, Mainardi JL, Brouqui P, Vandenesch F, Carta A, Lehnert F, et al. Bartonella (Rochalimaea) quintana endocarditis in three homeless men. N Engl J Med. 1995 Feb 16. 332(7):419-23. [Medline].

  37. Woolley MW, Gordon DL, Wetherall BL. Analysis of the first Australian strains of Bartonella quintana reveals unique genotypes. J Clin Microbiol. 2007 Jun. 45(6):2040-3. [Medline]. [Full Text].

  38. Yoda M, Hata M, Sezai A, Unosawa S, Furukawa N, Minami K. First report of Bartonella quintana endocarditis in Japan. Circ J. 2008 Jun. 72(6):1022-4. [Medline].

  39. Znazen A, Rolain JM, Hammami N, Kammoun S, Hammami A, Raoult D. High prevalence of Bartonella quintana endocarditis in Sfax, Tunisia. Am J Trop Med Hyg. 2005 May. 72(5):503-7. [Medline].

  40. Balakrishnan N, Menon T, Fournier PE, Raoult D. Bartonella quintana and Coxiella burnetii as causes of endocarditis, India. Emerg Infect Dis. 2008 Jul. 14(7):1168-9. [Medline]. [Full Text].

  41. Raoult D, Fournier PE, Vandenesch F, Mainardi JL, Eykyn SJ, Nash J, et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med. 2003 Jan 27. 163(2):226-30. [Medline].

  42. Fournier PE, Lelievre H, Eykyn SJ, Mainardi JL, Marrie TJ, Bruneel F, et al. Epidemiologic and clinical characteristics of Bartonella quintana and Bartonella henselae endocarditis: a study of 48 patients. Medicine (Baltimore). 2001 Jul. 80(4):245-51. [Medline].

  43. Foucault C, Barrau K, Brouqui P, Raoult D. Bartonella quintana Bacteremia among Homeless People. Clin Infect Dis. 2002 Sep 15. 35(6):684-9. [Medline].

  44. Koo M, Manalili S, Bankowski MJ, Sampath R, Hofstadler SA, Koo J. A "silent culture-negative" abdominal aortic mycotic aneurysm: Rapid detection of Bartonella species using PCR and high-throughput mass spectrometry. Hawaii Med J. 2010 Mar. 69(3):68-9. [Medline]. [Full Text].

  45. CLSI. Principles and Procedures for Blood Cultures: Approved Guidelines. 2007. Available at

  46. Larson AM, Dougherty MJ, Nowowiejski DJ, Welch DF, Matar GM, Swaminathan B, et al. Detection of Bartonella (Rochalimaea) quintana by routine acridine orange staining of broth blood cultures. J Clin Micro. June/1994. 32(6):1492-6. [Medline].

  47. Rahimian J, Raoult D, Tang YW, Hanna BA. Bartonella quintana endocarditis with positive serology for Coxiella burnetii. J Infect. Sept /2006. 53(3):e151-3. [Medline].

  48. Rolain JM, Broqui P, Koehler JE, Maguina C, Dolan MJ, and Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemo. June 2004. 48(6):1921-33. [Medline].

  49. Myers WF, Grossman DM, Wisseman CL Jr. Antibiotic susceptibility patterns in Rochalimaea quintana, the agent of trench fever. Antimicrob Agents Chemother. 1984. 25:690-3. [Medline].

  50. Rolain JM, Maurin M, Mallet MN, Parzy D, Raoult D. Culture and antibiotic susceptibility of Bartonella quintana in human erythrocytes. Antimicrob Agents Chemother. 2003 Feb. 47(2):614-9. [Medline].

  51. Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother. 2003 Jul. 47(7):2204-7. [Medline].

  52. Prutsky G, Domecq JP, Mori L, Bebko S, Matzumura M, Sabouni A, et al. Treatment outcomes of human bartonellosis: a systematic review and meta-analysis. Int J Infect Dis. 2013 Oct. 17(10):e811-9. [Medline].

  53. Cerimele F, Brown LF, Bravo F, Iher GM, Kouadio P, Arbiser JL, et al. Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor. Am J Pathol. Oct 2003. 163:1321-7. [Medline].

  54. Kostrzewski J. The epidemiology of trench fever. Bull Acad Pol Sci (Med). 1949. 7:233-63. [Medline].

  55. Popa C, Abdollahi-Roodsaz S, Joosten LA, Takahashi N, Sprong T, Matera G, et al. Bartonella quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun. Oct/2007. 75(10):4831-7. [Medline].

Dorsal view of female body louse, Pediculus humanus var corporis. This louse is a known vector responsible for transmission of epidemic typhus, trench fever, and Asiatic relapsing fever; it also causes dermatitic condition known as pediculosis. Image courtesy of Centers for Disease Control and Prevention.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.